Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Published in: Clinical Rheumatology 6/2003

01-12-2003 | Case Report

Aggressive and atypical manifestations of Erdheim-Chester disease

Authors: Eric M. Lyders, Shaifali Kaushik, Juan Perez-Berenguer, Daniel A. Henry

Published in: Clinical Rheumatology | Issue 6/2003

Login to get access

Abstract

Erdheim–Chester disease (ECD) is a disseminated non-Langerhans’ cell histiocytosis with multisystem involvement, including characteristic sclerotic musculoskeletal lesions. We present the case of a 27-year-old woman with a fulminant course and atypical involvement by ECD manifesting as extensive cerebrovascular disease and lytic musculoskeletal lesions. This case represents an unusual and aggressive presentation of ECD owing to the patient’s young age, the severity of the cerebrovascular involvement and the lytic osseous lesions.
Literature
1.
Jaffe HL (1972) Metabolic, degenerative, and inflammatory diseases of the bones and joints. Philadelphia, Lea & Febiger, 535–541
2.
Oweity T et al. (2002) Multiple system Erdheim–Chester disease with massive hypothalamic–sellar involvement and hypopituitarism. J Neurosurg 96:344–351PubMed
3.
Babu RP, Lansen TA, Chadburn A, Kasoff SS (1997) Erdheim–Chester disease of the central nervous system: report of two cases. J Neurosurg 86:888–892PubMed
4.
Veyssier-Belot C et al. (1996) Erdheim–Chester disease: clinical and radiologic characteristics of 59 cases. Medicine 75:157–168PubMed
5.
Ruiz-Hernandez G, Tajahuerce-Romera GM, Latorre-Ibanez MD, Vila-Fayos V, Lara-Pomares A (2000) Epiphyseal involvement in Erdheim–Chester disease: radiographic and scintigraphic findings in a case with lytic lesions. Nuklearmedizin. 39:N72–73
6.
Breuil V, Brocq O, Pellegrino C, Grimaud A, Euller-Ziegler L (2002) Erdheim–Chester disease: typical radiological bone features for a rare xanthogranulomatosis. Ann Rheum Dis 61:199–200CrossRefPubMed
7.
Shamburik RD, Brewer HB, Gochuico BR (2001) Erdheim–Chester disease: a rare multisystem histiocytic disorder associated with interstitial lung disease. Am J Med Sci 321:66–75PubMed
8.
Egan AJM et al. (1999) Erdheim–Chester disease: clinical, radiologic, and histopathologic findings in five patients with interstitial lung disease. Am J Surg Pathol 23:17–26CrossRefPubMed
9.
Murray D, Marshall M, England E, Mander J, Chakera TMH (2001) Erdheim–Chester disease. Clin Radiol 56:481–484CrossRefPubMed
10.
Evans S, Williams F (1986) Case report: Erdheim–Chester disease: polyostotic sclerosing histiocytosis. Clin Radiol 37:93–96PubMed
11.
Kenn W et al. (2000) Erdheim–Chester disease: evidence for a disease entity different for Langerhans cell histiocytosis? Three cases with detailed radiological and immunohistochemical analysis. Hum Pathol 31:734–739PubMed
12.
Lahey ME (1962) Prognosis in reticuloendotheliosis in children. J Pediatr 51:664–671
13.
Metadata
Title
Aggressive and atypical manifestations of Erdheim-Chester disease
Authors
Eric M. Lyders
Shaifali Kaushik
Juan Perez-Berenguer
Daniel A. Henry
Publication date
01-12-2003
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 6/2003
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-003-0784-4

Other articles of this Issue 6/2003

Clinical Rheumatology 6/2003 Go to the issue

Case Report

Kawasaki disease in an infant following immunisation with hepatitis B vaccine

Case Report

The burden of amyloidosis on the gastrointestinal tract of an ankylosing spondylitis patient

Letter

Pulmonary aneurysms in microscopic polyangiitis

Original Article

First carpometacarpal and interphalangeal osteoarthritis of the hand in patients with advanced hip or knee OA. Are there differences in the aetiology?

Case Report

Diabetic muscular infarction: emphasis on pathogenesis

Letter

Usefulness of technetium-99m tetrofosmin SPECT to detect abnormal myocardial perfusion in systemic lupus erythematosus or systemic sclerosis patients
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits